MM-344

Longer-Term Follow-Up of Patients Receiving Prophylactic Tocilizumab for the Reduction of Cytokine Release Syndrome in the Phase 1/2 MajesTEC-1 Study of Teclistamab in Relapsed/Refractory Multiple Myeloma

Niels WCJ van de Donk[1], Alfred L Garfall[2], Lotfi Benboubker[3], Katarina Uttervall[4], Kaz Groen[1], Laura Rosiñol[5], Jeffrey V Matous[6], Deeksha Vishwamitra[7], Caroline Hodin[8], Tara Stephenson[7], Keqin Qi[9], Athena Zuppa[10], Katherine Chastain[10], María-Victoria Mateos[11]

[1]Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands; [2]Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; [3]Hôpital Bretonneau, Centre Hospitalier Régional Universitaire, Tours, France; [4]Karolinska University Hospital, Stockholm, Sweden; [5]Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain; [6]Colorado Blood Cancer Institute and Sarah Cannon Research Institute, Denver, CO, USA; [7]Janssen Research & Development, Spring House, PA, USA; [8]Janssen Research & Development, Beerse, Antwerp, Belgium; [9]Janssen Research & Development, Titusville, NJ, USA; [10]Janssen Research & Development, Raritan, NJ, USA; [11]Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Centro de Investigación del Cáncer (IBMCC-USAL,CSIC), Salamanca, Spain

Key Takeaway

Prophylactic tocilizumab reduced the overall incidence of CRS with teclistamab by 65% relative to the pivotal MajesTEC-1 population, with no new safety signals or impact on response at longer follow-up

Conclusions

- Incidence of CRS with teclistamab was reduced from 72.1%, without prophylactic tocilizumab in the pivotal cohort of MajesTEC-1, to 25% in the prophylactic tocilizumab cohort (all events grade 1/2)
- With longer follow-up, no new safety signals or impact on response to teclistamab were observed
- Further data to inform potential risk factors for higher-grade CRS are needed
- Prophylactic tocilizumab may be considered to mitigate risk of CRS for outpatient dosing of teclistamab

Please scan QR code

Poster

Supplementary material

https://www.congresshub.com/Oncology/AM2024/Teclistamab/Donk

Copies of this presentation obtained through Quick Response (QR) Codes are for personal use only and may not be reproduced without permission from ASCO® or the author of this presentation.

Acknowledgments

We thank the patients who participated in the study and their families and caregivers, the physicians and nurses who cared for patients and supported this clinical trial, staff members at the study sites, and staff members involved in data collection and analyses. This study was funded by Janssen Research & Development, LLC. Medical writing support was provided by Maggie Hartman, PharmD, of Eloquent Scientific Solutions, and funded by Janssen Global Services, LLC. © 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. All rights reserved.

Disclosures

NWCJvdD has held a consulting/advisory role for Adaptive Biotechnologies, Amgen, Bayer, BMS, Celgene, Janssen, Novartis, Roche, Servier, and Takeda; and has received research funding from Amgen, BMS, Celgene, Cellectis, Janssen, and Novartis.

Introduction

- Teclistamab is the first approved B-cell maturation antigen × CD3 bispecific antibody (BsAb) for the treatment of triple-class exposed relapsed/refractory multiple myeloma, with weight-based dosing and the longest study follow-up of any BsAb in multiple myeloma[1-3]
- In the pivotal MajesTEC-1 study, 72.1% of patients had cytokine release syndrome (CRS; all grade 1/2 except 1 grade 3 event in 1 patient)[3,4]
- Teclistamab has been given successfully in the outpatient setting, using prophylactic tocilizumab to manage CRS[5-9]
- In a separate cohort, prophylactic tocilizumab prior to step-up dose (SUD) 1 reduced the incidence of CRS to 26% (all grade 1 and 2) at 2.6 months median follow-up[10]
  - Here, we present data with a longer median follow-up of 8.1 months in the prophylactic tocilizumab cohort (n=24) in MajesTEC-1

Methods

- Patients received teclistamab 1.5 mg/kg weekly (QW; phase 1 exploratory cohort) or a comparable fixed dose after a single dose of tocilizumab and SUD (**Figure 1**)
  - Tocilizumab 8 mg/kg was administered intravenously ≤4 hours before the first teclistamab SUD
  - Premedications during the teclistamab SUD schedule were dexamethasone, acetaminophen, and diphenhydramine
  - Hospitalization was required for 48 hours after each SUD and after the first treatment dose
- CRS management with tocilizumab treatment was permitted for grade 1 and recommended for grade ≥2
- CRS as an adverse event (AE) was graded per Lee et al[11]

Figure 1: Dosing schedule for patients receiving teclistamab and prophylactic tocilizumab



[a]2–4 days were allowed between SUD 1, SUD 2, and treatment dose. [b]Less frequent dosing (eg, Q2W) starting cycle 3. Q2W, every other week.

Results

- 24 patients received prophylactic tocilizumab prior to SUD 1 of teclistamab
  - Median follow-up: 8.1 months (range, 0.9–13.2)
- Patient demographics and disease characteristics were generally consistent with the MajesTEC-1 pivotal population[3] (**Table 1**)

Table 1: Baseline characteristics

Characteristics	All patients (N=24)[a]
Age, years, median (range)	72 (50–82)
Male, n (%)	14 (58.3)
Race, n (%)	
White	19 (79.2)
Other	2 (8.3)
Not reported	3 (12.5)
ECOG PS score, n (%)	
0	13 (54.2)
1	11 (45.8)
Extramedullary plasmacytomas,[a] n (%)	
0	19 (79.2)
≥1	5 (20.8)
High-risk cytogenetics,[b] n (%)	6 (26.1)
ISS stage, n (%)	
I	16 (66.7)
II	7 (29.2)
III	1 (4.2)
Prior lines of therapy, median (range)	4 (2–9)
Triple-class refractory,[c] n (%)	14 (58.3)
% BMPCs (biopsy or aspirate), n (%)	
<30	16 (66.7)
30–59	3 (12.5)
≥60	5 (20.8)

Data cut-off: Nov 1, 2023. [a]≥1 soft tissue plasmacytoma not associated with bone. [b]n=23; high-risk cytogenetics included del(17p), t(4;14), t(14;16). [c]≥1 proteasome inhibitor, ≥1 immunomodulatory drug, and an anti-CD38 monoclonal antibody. BMPC, bone marrow plasma cell; ECOG PS, Eastern Cooperative Oncology Group performance status; ISS, International Staging System.


CRS incidence and severity

- 25% CRS with prophylactic tocilizumab (**Figure 2**)
  - Grade 1 (n=2), grade 2 (n=4); no grade 3 events
  - All initial events occurred during SUD; 3 recurrent events
  - Median time to onset: 2 days (range, 1–3)
  - Median duration: 2 days (range, 2–4)
  - All events resolved

CRS and baseline disease characteristics

- No disease characteristic associated with CRS, consistent with the MajesTEC-1 pivotal population[4] (**Table 2**)
  - Small sample size precludes clinically meaningful conclusions

Figure 2: CRS incidence and severity



[a]Pivotal MajesTEC-1 population.

Table 2: CRS by grade and baseline characteristics

Prophylactic tocilizumab cohort (N=24)			
Characteristic	**No CRS (n=18)**	**CRS Grade 1 (n=2)**	**CRS Grade 2 (n=4)**
BMPCs, %, median (range)	8.0 (0–80)	19.0 (8–30)	62.5 (30–80)
ISS stage,[a] %			
I	72.2	50	50
II	22.2	50	50
III	5.6	0	0
No. of EMPs, median (range)	0 (0–4)	0 (0)	0 (0–2)

Data cut-off: Nov 1, 2023. [a]Derived based on the combination of serum β_2-microglobulin and albumin. EMP, extramedullary plasmacytoma.

Safety

- The safety profile of this cohort was generally consistent with the pivotal MajesTEC-1 population,[12] including incidence of any-grade and grade 3/4 infections (**Table 3**)
- Grade 3/4 infections (25%) included:
  - Pneumonia (n=4)
  - Bacterial infection (n=1)
  - Diverticulitis (n=1)
  - Cytomegalovirus infection (n=1)
  - Sepsis (n=1)
  - Septic shock (n=1)
- 5 patients had 10 neurotoxicity events (ie, neurological AE considered related by investigator) including:
  - Headache, immune effector cell–associated neurotoxicity syndrome, myoclonus, dizziness, and insomnia
  - All events were grade 1/2
  - All events resolved except for grade 2 headache
- Grade 5 pulmonary embolism occurred 20 days after the last teclistamab dose

Table 3: AEs observed with teclistamab and prophylactic tocilizumab

Prophylactic tocilizumab cohort (N=24)		
TEAE, n[a] (%)	**Any Grade**	**Grade 3/4**
Infections[b]	19 (79.2)	6 (25.0)
Neutropenia	15 (62.5)	15 (62.5)
Anemia	14 (58.3)	6 (25.0)
Thrombocytopenia	12 (50.0)	6 (25.0)
Lymphopenia	9 (37.5)	9 (37.5)
Leukopenia	6 (25.0)	5 (20.8)
Increased lipase	6 (25.0)	5 (20.8)

[a]Rate of any-grade TEAEs are listed if occurring at grade 3/4 in ≥20% of patients. [b]Rate of any-grade infections and grade 3/4 in the MajesTEC-1 pivotal was 63.0% and 30.9%, respectively, at 7.2 months median follow-up.


Response to teclistamab

- Responses were similar to the MajesTEC-1 pivotal population[12] (**Figure 3**)
  - The lower complete response (CR) or better rate in the prophylactic tocilizumab cohort is likely due to limited availability of bone marrow samples to confirm CR and duration of follow-up
  - At 8.1 months median follow-up, no impact on teclistamab efficacy was observed

Cytokine profiles

- A single dose of prophylactic tocilizumab blocks interleukin-6 receptor occupancy for ~10 days, covering the teclistamab SUD schedule (**Supplemental Figure 1** and **Supplemental Figure 2**)

Figure 3: Teclistamab response rates



[a]22 of 24 patients evaluable. Response-evaluable were defined as patients who have received ≥1 study treatment and have ≥1 postbaseline response evaluation by the investigator. ORR, overall response rate; PR, partial response; sCR, stringent complete response; VGPR, very good partial response.

References

1. TECVAYLI® (teclistamab). Summary of product characteristics. Leiden, Netherlands: Janssen Biologics BV; 2022. 2. TECVAYLI® (teclistamab-cqyv). Prescribing information. Horsham, PA: Janssen Biotech, Inc; 2022. 3. Moreau P, et al. *New Engl J Med* 2022;387:495-505. 4. Martin TG, et al. *Cancer* 2023;129:2035-46. 5. Trudel S, et al. *Blood* 2022;140(suppl 1):1363-5. 6. Kauer J, et al. *J Immunother Cancer* 2020;8:e000621. 7. Scott, S et al. *Blood Cancer J* 2023;13:191. 8. Kowalski A, et al. *Blood* 2023;142(supplement 1):4709. 9. Varshavsky-Yanovsky AN, et al. *Hemasphere* 2023;7(suppl):e605007f. 10. van de Donk NWCJ, et al. Presented at ASCO; June 2–6, 2023; Chicago, IL, USA & Virtual. Poster #8033. 11. Lee DW, et al. *Blood* 2014;124:188-95. 12. Garfall AL, et al. Presented at ASCO; May 31–June 4, 2024; Chicago, IL, USA & Virtual. Poster #7540.

Multiple Myeloma

Presented by D Odukoya at the Society of Hematologic Oncology (SOHO) Annual Meeting; September 4–7, 2024; Houston, TX, USA